These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 15953019)

  • 1. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of extended-spectrum beta-lactamases in South America.
    Villegas MV; Kattan JN; Quinteros MG; Casellas JM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():154-8. PubMed ID: 18154539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of extended-spectrum beta-lactamases.
    BMJ Group
    Drug Ther Bull; 2008 Mar; 46(3):21-4. PubMed ID: 18337463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania.
    Ndugulile F; Jureen R; Harthug S; Urassa W; Langeland N
    BMC Infect Dis; 2005 Oct; 5():86. PubMed ID: 16225701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
    Kader AA; Angamuthu K
    Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of extended spectrum beta lactamase mediated resistance in neonatal septicemia.
    Vinodkumar CS; Neelagund YF
    Indian J Pathol Microbiol; 2006 Oct; 49(4):616-9. PubMed ID: 17183878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-resistance analysis of Gram-negative bacilli producing extended-spectrum beta-lactamases in lower respiratory tract infection].
    Long J; Lü SC
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):439-40, 444. PubMed ID: 15090319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
    Maltezou HC
    Int J Antimicrob Agents; 2009 May; 33(5):405.e1-7. PubMed ID: 19095416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extended spectrum beta-lactamse (ESBL)-induced antibiotics resistance in gram-negative agents: what should be watched in intensive care medicine?].
    Kola A; Gastmeier P
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Sep; 38(9):573-6. PubMed ID: 12975735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
    Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance in gram-negative bacteria: enterobacteriaceae.
    Paterson DL
    Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.